GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » EBITDA Margin %

Qiagen NV (Qiagen NV) EBITDA Margin % : 35.92% (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Qiagen NV EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Qiagen NV's EBITDA for the three months ended in Dec. 2023 was $183 Mil. Qiagen NV's Revenue for the three months ended in Dec. 2023 was $509 Mil. Therefore, Qiagen NV's EBITDA margin for the quarter that ended in Dec. 2023 was 35.92%.


Qiagen NV EBITDA Margin % Historical Data

The historical data trend for Qiagen NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV EBITDA Margin % Chart

Qiagen NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.93 38.27 39.76 36.39 35.04

Qiagen NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.22 36.12 23.95 34.34 35.92

Competitive Comparison of Qiagen NV's EBITDA Margin %

For the Diagnostics & Research subindustry, Qiagen NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Qiagen NV's EBITDA Margin % falls into.



Qiagen NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Qiagen NV's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=688.555/1965.311
=35.04 %

Qiagen NV's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=182.887/509.162
=35.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qiagen NV  (NYSE:QGEN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Qiagen NV EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Qiagen NV's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Qiagen NV (Qiagen NV) Business Description

Address
Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Executives
Prof. Dr. Elaine R. Mardis Supervisory Board
Roland Sackers Board of Directors
Thierry Bernard Board of Directors
Lawrence A. Rosen Supervisory Board